TY - JOUR
T1 - Advanced glycation end products and their circulating receptors predict cardiovascular disease mortality in older community-dwelling women
AU - Semba, Richard D.
AU - Ferrucci, Luigi
AU - Sun, Kai
AU - Beck, Justine
AU - Dalal, Mansi
AU - Varadhan, Ravi
AU - Walston, Jeremy
AU - Guralnik, Jack M.
AU - Fried, Linda P.
N1 - Funding Information:
This work was supported by National Institute on Aging Grant R01 AG027012, R01 AG029148, NIH-NCRR, OPD-GCRC grant RR00722, and NIA Contract N01-AG12112, the Johns Hopkins Older Americans’ Independence Center, and the Intramural Research Program, National Institute on Aging, NIH.
PY - 2009/4
Y1 - 2009/4
N2 - Aims: To characterize the relationship between advanced glycation end products (AGEs) and circulating receptors for AGEs (RAGE) with cardiovascular disease mortality. Methods: The relationships between serum AGEs, total RAGE (sRAGE), and endogenous secretory RAGE (esRAGE), and mortality were characterized in 559 community-dwelling women, † 65 years, in Baltimore, Maryland. Results: During 4.5 years of follow-up, 123 (22%) women died, of whom 54 died with cardiovascular disease. The measure of serum AGEs was carboxymethyl-lysine (CML), a dominant AGE. Serum CML predicted cardiovascular disease mortality (Hazards Ratio [HR] for highest vs lower three quartiles, 1.94, 95% Confidence Interval [CI] 1.08-3.48, p=0.026), after adjusting for age, race, body mass index, and renal insufficiency. Serum sRAGE (ng/mL) and esRAGE (ng/mL) predicted cardiovascular disease mortality (HR per 1 Standard Deviation [SD] 1.27, 95% CI 0.98-1.65, p=0.07; HR 1.28, 95% CI 1.02-1.63, p=0.03), after adjusting for the same covariates. Among non-diabetic women, serum CML, sRAGE, and esRAGE, respectively, predicted cardiovascular disease mortality (HR for highest vs lower three quartiles, 2.29, 95% CI 1.21-4.34, p=0.01; HR per 1 SD, 1.24, 95% CI 0.92-1.65, p=0.16; HR per 1 SD 1.45, 95% CI 1.08-1.93, p=0.01), after adjusting for the same covariates. Conclusions: High circulating AGEs and RAGE predict cardiovascular disease mortality among older community-dwelling women. AGEs are a potential target for interventions, as serum AGEs can be lowered by change in dietary pattern and pharmacological treatment.
AB - Aims: To characterize the relationship between advanced glycation end products (AGEs) and circulating receptors for AGEs (RAGE) with cardiovascular disease mortality. Methods: The relationships between serum AGEs, total RAGE (sRAGE), and endogenous secretory RAGE (esRAGE), and mortality were characterized in 559 community-dwelling women, † 65 years, in Baltimore, Maryland. Results: During 4.5 years of follow-up, 123 (22%) women died, of whom 54 died with cardiovascular disease. The measure of serum AGEs was carboxymethyl-lysine (CML), a dominant AGE. Serum CML predicted cardiovascular disease mortality (Hazards Ratio [HR] for highest vs lower three quartiles, 1.94, 95% Confidence Interval [CI] 1.08-3.48, p=0.026), after adjusting for age, race, body mass index, and renal insufficiency. Serum sRAGE (ng/mL) and esRAGE (ng/mL) predicted cardiovascular disease mortality (HR per 1 Standard Deviation [SD] 1.27, 95% CI 0.98-1.65, p=0.07; HR 1.28, 95% CI 1.02-1.63, p=0.03), after adjusting for the same covariates. Among non-diabetic women, serum CML, sRAGE, and esRAGE, respectively, predicted cardiovascular disease mortality (HR for highest vs lower three quartiles, 2.29, 95% CI 1.21-4.34, p=0.01; HR per 1 SD, 1.24, 95% CI 0.92-1.65, p=0.16; HR per 1 SD 1.45, 95% CI 1.08-1.93, p=0.01), after adjusting for the same covariates. Conclusions: High circulating AGEs and RAGE predict cardiovascular disease mortality among older community-dwelling women. AGEs are a potential target for interventions, as serum AGEs can be lowered by change in dietary pattern and pharmacological treatment.
KW - Advanced glycation end products
KW - Aging
KW - Atherosclerosis
KW - Cardiovascular disease
KW - Mortality
UR - http://www.scopus.com/inward/record.url?scp=66849135104&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=66849135104&partnerID=8YFLogxK
U2 - 10.1007/BF03325227
DO - 10.1007/BF03325227
M3 - Article
C2 - 19448391
AN - SCOPUS:66849135104
SN - 1594-0667
VL - 21
SP - 182
EP - 190
JO - Aging Clinical and Experimental Research
JF - Aging Clinical and Experimental Research
IS - 2
ER -